Abstract

This is a phase-II study of 141W94/VX-478 plus 3TC plus ZDV or indinavir plus nevirapine plus 3TC plus stavudine in subjects previously treated with 141W94/VX-478. Approximately 94 subjects will be studied. The study population will consist of subjects who have successfully been treated with a regimen that includes 141W94/VX-478, OR subjects who have failed or are intolerant to a treatment regimen that includes 141W94/VX-478. Subjects enrolled to ACTG 347 who prematurely discontinued study medications and were treated with open-label IDV + NVP + 3TC + d4T will also be eligible to participate. Subjects will receive one of two treatment regimens: Arm A (subjects with < 500 copies HIV-1 RNA/mL on a regimen containing 141W94/VX-478) will receive 141W94/VX-478 (1200 mg q 12 hr) plus ZDV (300 mg q 12 hr) or d4T (40 mg q 12 hr) plus 3TC (150 mg q 12 hr). Arm B (subjects with 3 500 copies HIV-1 RNA/mL or intolerance to a regimen containing 141W94/VX-478) will receive IDV (1000 mg q 8 hr) plus NVP (200 mg bid) plus 3TC (150 mg bid) plus d4T (40 mg bid).

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR000096-37
Application #
6277060
Study Section
Project Start
1997-12-01
Project End
1998-11-30
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
37
Fiscal Year
1998
Total Cost
Indirect Cost

  Institution

Name
New York University
Department
Type
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10016

  Publications

Jun, Gyungah R; Chung, Jaeyoon; Mez, Jesse et al. (2017) Transethnic genome-wide scan identifies novel Alzheimer's disease loci. Alzheimers Dement 13:727-738
Homann, O R; Misura, K; Lamas, E et al. (2016) Whole-genome sequencing in multiplex families with psychoses reveals mutations in the SHANK2 and SMARCA1 genes segregating with illness. Mol Psychiatry 21:1690-1695
Ridge, Perry G; Hoyt, Kaitlyn B; Boehme, Kevin et al. (2016) Assessment of the genetic variance of late-onset Alzheimer's disease. Neurobiol Aging 41:200.e13-200.e20
Hohman, Timothy J; Bush, William S; Jiang, Lan et al. (2016) Discovery of gene-gene interactions across multiple independent data sets of late onset Alzheimer disease from the Alzheimer Disease Genetics Consortium. Neurobiol Aging 38:141-150
Jun, G; Ibrahim-Verbaas, C A; Vronskaya, M et al. (2016) A novel Alzheimer disease locus located near the gene encoding tau protein. Mol Psychiatry 21:108-17
Ebbert, Mark T W; Boehme, Kevin L; Wadsworth, Mark E et al. (2016) Interaction between variants in CLU and MS4A4E modulates Alzheimer's disease risk. Alzheimers Dement 12:121-129
Hohman, Timothy J; Cooke-Bailey, Jessica N; Reitz, Christiane et al. (2016) Global and local ancestry in African-Americans: Implications for Alzheimer's disease risk. Alzheimers Dement 12:233-43
Beecham, Gary W; Dickson, Dennis W; Scott, William K et al. (2015) PARK10 is a major locus for sporadic neuropathologically confirmed Parkinson disease. Neurology 84:972-80
Wang, Li-San; Naj, Adam C; Graham, Robert R et al. (2015) Rarity of the Alzheimer disease-protective APP A673T variant in the United States. JAMA Neurol 72:209-16
Mukherjee, Shubhabrata; Walter, Stefan; Kauwe, John S K et al. (2015) Genetically predicted body mass index and Alzheimer's disease-related phenotypes in three large samples: Mendelian randomization analyses. Alzheimers Dement 11:1439-1451

Showing the most recent 10 out of 470 publications